Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ACN
3. NVDA
4. GOOGL
5. MU
6. DFTX
7. USO
8. APGE
9. ABBV
10. NAVN

Go back to Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)

Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Bil

November 4, 2021 7:00 AM EDT

IND for CNP-104 Accepted by FDA; Clinical Trials Planned for the End of 2021

Ironwood to Make a Payment of approximately $20 Million in Upfront and Near-Term Milestones and up to $475 Million in Long-Term Commercial and Regulatory Milestones and Royalties to COUR

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:... More